SCHEMBL7784263

SCHEMBL7784263

NCC(O)CC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
KDM4E B2RXH2 2/20 0.46
GMNN O75496 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25852161 1.00 TP53 (0.48) TP53KDM4EGMNNLMNAMAPT
SCHEMBL14382085 0.98 TP53 (0.44) TP53KDM4EGMNNLMNAMAPT
SCHEMBL23870582 0.91 TP53 (0.38) TP53KDM4EGMNNLMNAMAPT
SCHEMBL29067960 0.87
SCHEMBL29067957 0.87
SCHEMBL23503456 0.87 TP53 (0.37) TP53KDM4EGMNNLMNAMAPT
SCHEMBL20354169 0.85 KDM4E (0.42) TP53KDM4E
SCHEMBL5101014 0.80 KDM4E (0.39) TP53KDM4E
SCHEMBL28622321 0.78 ALDH1A1 (0.38) TP53KDM4ELMNAMAPT
SCHEMBL7906892 0.78 ALDH1A1 (0.38) TP53KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0363108-B1 Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations EASTMAN KODAK CO (US) 1994-07-13 EP claimed
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] PHENEX PHARMACEUTICALS AG (DE) 2019-05-28 US disclosed
CN-107076728-A Analytical method for diluting biological sample components 立佳有限公司 2017-08-18 CN disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
EP-2855440-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] Phenex Pharmaceuticals AG (DE) 2015-04-08 EP disclosed
WO-2013178362-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2013-12-05 WO disclosed
CN-1100534-C 2-(1H-4(5)-imidazoyl cyclopropyl derivatives GLIATECH INC (US) 2003-02-05 CN disclosed
EP-0837679-B1 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES GLIATECH INC (US) 2001-10-24 EP disclosed
US-6008240-A AN ANTAGONIST OF HISTAMINE H3 RECEPTORS; FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE (HYPER OR HYPOTENSION), GASTROINTESTINAL DISORDERS, CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS GLIATECH, INC. (US) 1999-12-28 US disclosed
US-5990317-A HISTAMINE H3 RECEPTOR ANTAGONIST FOR TREATING CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS GLIATECH, INC. (US) 1999-11-23 US disclosed
EP-0837679-A4 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES GLIATECH INC (US) 1999-03-03 EP disclosed
CN-1192143-A 2-(1H-4(5)-imidazoyl cyclopropyl derivatives GLIATECH INC (US) 1998-09-02 CN disclosed
EP-0837679-A1 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES Gliatech, Inc. (US) 1998-04-29 EP disclosed
WO-1996038141-A1 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES GLIATECH, INC. (US) 1996-12-05 WO disclosed
CN-1113436-A Potentiation of drug response LILLY CO ELI (US) 1995-12-20 CN disclosed
CN-1104889-A Cessation of tobacco use LILLY CO ELI (US) 1995-07-12 CN disclosed
US-4990666-A Contacting with Raney cobalt; heating, pressurization W. R. GRACE & CO.-CONN. (US) 1991-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] RORA, RORB, RORC TP53 3409/4885KDM4E 2241/4885GMNN 4522/4885
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] RORA, RORB, RORC TP53 3471/4885KDM4E 2217/4885GMNN 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.